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 BACKGROUND Every year the influenza vaccine is reformulated, so estimating the influenza vaccine effectiveness (VE) every season and in an early stage is 
important to support public health decisions. Since 2008, Portugal has been participating with the EuroEVA study in the I-MOVE (Influenza Monitoring Vaccine 
Effectiveness in Europe), financed by ECDC and coordinated by Epiconcept, which main objective is to estimate seasonal and pandemic vaccine effectiveness 
during and after the influenza season. In this context, we used two methods to estimate VE for the 2010-11 seasonal influenza vaccine, both in the elderly and 
in all age groups. 
 
Influenza vaccine effectiveness 2010-11 in Portugal 
obtained by two methods:  results from the EuroEVA study 
Ausenda Machado 1, B. Nunes 1, P. Pechirra 2, P. Gonçalves 2 , P. Conde 2, R. Guiomar 2, I. Falcão 3 
1 Department of Epidemiology  and  2 National Influenza Reference Laboratory of the Instituto Nacional de 
Saúde Dr. Ricardo Jorge, Portugal, 3 General Directorate of Health, Portugal 
TEST NEGATIVE DESIGN (TND) SCREENING METHOD 
General Design  
A case-control approach was used, where laboratory confirmed influenza 
cases (ILI+) were compared to laboratory negative influenza ILI patients (ILI-).  
General Design 
The 2010-11 seasonal vaccine coverage (VC) was compared between a sample of 
ILI cases positive for influenza with the vaccine coverage estimated in the general 
population. Vaccine coverage in the population was obtained from a population 
based sample (ECOS sample), that corresponds to 3208 individuals. 
METHODS 
On a weekly basis, each GP selected systematically ILI patients using the EU ILI 
case definition.  
METHODS 
•Standardized questionnaire: one respondent by household (proxy for the rest of 
the household members).  Information on the vaccine status, ILI symptoms 
manifested from September to the interview and presence of chronic conditions. 
CASES (ILI+) 
(positive for any influenza virus) 
CONTROLS (ILI-) 
(negative for any influenza virus) 
 
2 ILI cases with  
less then 65 years 
  
All  ILI cases with 
65 years and above 
Sample of GP’s 
Systematic  selection 
Each GP has different starting  day of the week – 
 from Monday to Thursday 
Data collection by the GP 
1. Standardized questionnaire: data on 
confounding factors and effect modifiers; 
2. Nasopharyngeal swab 
Laboratory analysis 
(RT-PCR / Culture) 
FIGURE 1.DESIGN AND  RECRUITMENT FLOW PROCESS   
Vaccination status 
Individuals vaccinated more than 14 days before disease onset. 
Statistical analysis 
VE was estimated as one minus the odds ratio of being vaccinated in cases versus 
controls adjusted for confounders by logistic regression. 
RESULTS 
 
Mobile phones 
(n=445) 
  
Landline phones 
(n=629) 
ECOS sample 
A sample of 1074 households stratified by region  
(homogeneous allocation)  
selected from  a dual sample frame- random digit dialing 
Data collection by  CATI (Computer Assisted Telephone interview) 
Statistical analysis 
VE was estimated by comparing the proportion of cases vaccinated to the vaccine 
coverage in the source population using the Orenstein formula and the Farrington 
method to adjust for confounders.  
VC CASES (ILI +) 
(positive for any influenza virus) 
VC  COMMUNITY CONTROLS 
Data analysis 
Vaccine coverage estimates weighted by sex and age of the Portuguese population 
Vaccination status 
Individuals vaccinated more than 14 days before disease onset. 
FIGURE 2. DESIGN AND RECRUITMENT FLOW PROCESS   
RESULTS 
 
CONCLUSIONS  VE point estimates obtained by the two methods were very similar and an explanation for this consistency could be the fact that the 
seasonal vaccine coverage estimates between ILI- (17.4%) and the population based telephone survey (17.5%) were also very close. Nevertheless, and due 
to small sample size, our study was unable to estimate VE for specific seasonal vaccine target groups. Further efforts should be done to increase sample size, 
mainly in the elderly population.  
Community control ILI + (v/n) 
All 17.5 4.2 (6/143) 
0-64 yrs 10.8 2.9 (4/139) 
≥65  yrs 48.3 50.0 (2/4) 
No chronic 9.7 2.4 (3/127) 
Any chronic 33.0 18.8 (3/16) 
FIGURE 3. VACCINE COVERAGE IN CASES (ILI+) AND 
CONTROLS (ILI-) 
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TABLE 2. VACCINE COVERAGE  ON CASES ILI+ AND COMMUNITY 
CONTROL, BY AGE GROUP AND PRESENCE OF A CHRONIC CONDITION 
v – nr of vaccinated; n – nr of cases 
Crude Adjusted* 
VE (%) CI95% VE (%) CI95% 
All 79.4 53.4-90.9 63.9 16.9-84.3 
0-64 yrs 87.2 65.3-95.2 71.3 22.4-89.4 
65 + yrs** 
No chronic 77.5 29.3-92.8 64.2 18.7-91.8 
Any chronic** 
TABLE 3. CRUDE AND ADJUSTED 2010-11 VACCINE EFFECTIVENESS  
AGAINST ILI+, BY AGE GROUP AND PRESENCE OF A CHRONIC CONDITION 
Crude Adjusted* 
VE CI95% VE CI95% 
79.7 44.2-93.6 59.0 -61.8 – 89.6 
* Adjusted for confounding (age group and presence of chronic diseases) using the 
Farrington method 
** Not computed due to small sample size 
TABLE  1. CRUDE AND ADJUSTED SEASONAL 2010-11 
VACCINE EFFECTIVENESS AGAINST INFLUENZA 
The crude vaccine effectiveness 
estimate was 79.7%, with 
statistical significance (Table 1).  
 
After the adjustment for 
confounders, via non 
conditional logistic regression, 
the VE estimates decreased to 
59% with no statistical 
significance and presenting a 
very low precision. 
In this season, 2010-2011, the 
seasonal vaccine coverage in 
Controls was significantly higher 
(17.4%) than in All Influenza 
cases (ILI+) (4.2%) (Figure 3). 
* Data used in the estimates from week 45 till week 11; VE estimates 
adjusted for age group, pandemic and seasonal vaccine 2009-10, any chronic 
disease, target group and month of onset; 
Crude 2010-11 seasonal 
VE estimate was 79.4% 
(CI95% 53-91) (Table 3).  
 
After adjustment, the 
VE estimates decreased 
to 64% (CI95% 17-84), 
all results  statistically 
significant. 
Considering  the Screening 
method, the vaccine 
coverage in controls (from 
the community) was higher 
than the coverage in ILI+ 
cases (Table 2).  
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